- Home
- ENSC vs EVOK Comparison
ENSC vs EVOK Comparison
Compare ENSC & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- EVOK
- Stock Information
- Founded
- ENSC 2003
- EVOK 2007
- Country
- ENSC United States
- EVOK United States
- Employees
- ENSC N/A
- EVOK 3
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- ENSC Health Care
- EVOK Health Care
- Exchange
- ENSC Nasdaq
- EVOK Nasdaq
- Market Cap
- ENSC 6.4M
- EVOK 7.6M
- IPO Year
- ENSC N/A
- EVOK 2013
- Fundamental
- Price
- ENSC $2.18
- EVOK $4.90
- Analyst Decision
- ENSC
- EVOK
- Analyst Count
- ENSC 0
- EVOK 0
- Target Price
- ENSC N/A
- EVOK N/A
- AVG Volume (30 Days)
- ENSC 166.0K
- EVOK 27.4K
- Earning Date
- ENSC 11-07-2025
- EVOK 11-07-2025
- Dividend Yield
- ENSC N/A
- EVOK N/A
- EPS Growth
- ENSC N/A
- EVOK N/A
- EPS
- ENSC N/A
- EVOK N/A
- Revenue
- ENSC $7,413,722.00
- EVOK $12,794,859.00
- Revenue This Year
- ENSC N/A
- EVOK $57.38
- Revenue Next Year
- ENSC N/A
- EVOK $59.57
- P/E Ratio
- ENSC N/A
- EVOK N/A
- Revenue Growth
- ENSC 415.58
- EVOK 70.02
- 52 Week Low
- ENSC $1.62
- EVOK $1.94
- 52 Week High
- ENSC $14.67
- EVOK $12.32
- Technical
- Relative Strength Index (RSI)
- ENSC 45.96
- EVOK 52.02
- Support Level
- ENSC $2.07
- EVOK $4.53
- Resistance Level
- ENSC $2.26
- EVOK $4.69
- Average True Range (ATR)
- ENSC 0.20
- EVOK 0.27
- MACD
- ENSC -0.04
- EVOK 0.06
- Stochastic Oscillator
- ENSC 20.83
- EVOK 61.43
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.